FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2532584865> ?p ?o ?g. }

• W2532584865 endingPage "1913" @default.
• W2532584865 startingPage "1905" @default.
• W2532584865 abstract "The purpose of this study was to examine the safety and efficacy of cangrelor in patients with stable angina (SA) or acute coronary syndrome (ACS). The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding. Whether this benefit is consistent across SA and ACS has not been explored fully. The CHAMPION PHOENIX trial compared periprocedural administration of cangrelor or clopidogrel, with either a 300- or 600-mg loading dose for the prevention of periprocedural complications in patients undergoing percutaneous coronary intervention. Among the 10,942 patients in the modified intention to treat population, 6,358 patients were classified as having SA, and 4,584 patients had ACS (including unstable angina, non ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction) at randomization. The primary composite endpoint was death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 h. A key secondary endpoint was stent thrombosis, and the primary safety endpoint was GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) severe bleeding. Cangrelor consistently reduced the primary endpoint in SA and ACS (odds ratio [OR]: 0.83 [95% confidence interval (CI): 0.67 to 1.01] and OR: 0.71 [95% CI: 0.52 to 0.96], respectively; interaction p = 0.41). Cangrelor also consistently reduced stent thrombosis in SA and ACS (OR: 0.55 [95% CI: 0.30 to 1.01] and OR: 0.67 [95% CI: 0.42 to 1.06], respectively; interaction p = 0.62). The impact of cangrelor on GUSTO severe/moderate bleeding was also similar for SA and ACS (OR: 1.49 [95% CI: 0.67 to 3.33] and OR: 1.79 [95% CI: 0.79 to 4.07], respectively; interaction p = 0.75). The benefits and risks of cangrelor were consistent in patients with SA and ACS. (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI] [CHAMPION PHOENIX] [CHAMPION]; NCT01156571)" @default.
• W2532584865 created "2016-10-28" @default.
• W2532584865 creator A5003831287 @default.
• W2532584865 creator A5007026783 @default.
• W2532584865 creator A5008066011 @default.
• W2532584865 creator A5010571732 @default.
• W2532584865 creator A5010936003 @default.
• W2532584865 creator A5039432822 @default.
• W2532584865 creator A5046629853 @default.
• W2532584865 creator A5047914225 @default.
• W2532584865 creator A5060370891 @default.
• W2532584865 creator A5062843291 @default.
• W2532584865 creator A5065347832 @default.
• W2532584865 creator A5069820090 @default.
• W2532584865 creator A5086306721 @default.
• W2532584865 creator A5088217204 @default.
• W2532584865 date "2016-09-01" @default.
• W2532584865 modified "2023-10-18" @default.
• W2532584865 title "Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention" @default.
• W2532584865 cites W1017377764 @default.
• W2532584865 cites W1993893954 @default.
• W2532584865 cites W2009883495 @default.
• W2532584865 cites W2020353475 @default.
• W2532584865 cites W2038763263 @default.
• W2532584865 cites W2050027713 @default.
• W2532584865 cites W2053379248 @default.
• W2532584865 cites W2068984773 @default.
• W2532584865 cites W2071686230 @default.
• W2532584865 cites W2084673482 @default.
• W2532584865 cites W2100321613 @default.
• W2532584865 cites W2102951688 @default.
• W2532584865 cites W2103090059 @default.
• W2532584865 cites W2104191255 @default.
• W2532584865 cites W2112857503 @default.
• W2532584865 cites W2123112974 @default.
• W2532584865 cites W2125043491 @default.
• W2532584865 cites W2136228924 @default.
• W2532584865 cites W2140501627 @default.
• W2532584865 cites W2146338929 @default.
• W2532584865 cites W2150343380 @default.
• W2532584865 cites W2150655309 @default.
• W2532584865 cites W2153107785 @default.
• W2532584865 cites W2153139125 @default.
• W2532584865 cites W2166950143 @default.
• W2532584865 cites W2167565049 @default.
• W2532584865 cites W2169387542 @default.
• W2532584865 cites W2260370392 @default.
• W2532584865 cites W2272962241 @default.
• W2532584865 cites W2279877846 @default.
• W2532584865 cites W3030817736 @default.
• W2532584865 cites W34658592 @default.
• W2532584865 cites W4376848313 @default.
• W2532584865 cites W68793142 @default.
• W2532584865 doi "https://doi.org/10.1016/j.jcin.2016.06.046" @default.
• W2532584865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27659566" @default.
• W2532584865 hasPublicationYear "2016" @default.
• W2532584865 type Work @default.
• W2532584865 sameAs 2532584865 @default.
• W2532584865 citedByCount "37" @default.
• W2532584865 countsByYear W25325848652016 @default.
• W2532584865 countsByYear W25325848652017 @default.
• W2532584865 countsByYear W25325848652018 @default.
• W2532584865 countsByYear W25325848652019 @default.
• W2532584865 countsByYear W25325848652020 @default.
• W2532584865 countsByYear W25325848652021 @default.
• W2532584865 countsByYear W25325848652022 @default.
• W2532584865 countsByYear W25325848652023 @default.
• W2532584865 crossrefType "journal-article" @default.
• W2532584865 hasAuthorship W2532584865A5003831287 @default.
• W2532584865 hasAuthorship W2532584865A5007026783 @default.
• W2532584865 hasAuthorship W2532584865A5008066011 @default.
• W2532584865 hasAuthorship W2532584865A5010571732 @default.
• W2532584865 hasAuthorship W2532584865A5010936003 @default.
• W2532584865 hasAuthorship W2532584865A5039432822 @default.
• W2532584865 hasAuthorship W2532584865A5046629853 @default.
• W2532584865 hasAuthorship W2532584865A5047914225 @default.
• W2532584865 hasAuthorship W2532584865A5060370891 @default.
• W2532584865 hasAuthorship W2532584865A5062843291 @default.
• W2532584865 hasAuthorship W2532584865A5065347832 @default.
• W2532584865 hasAuthorship W2532584865A5069820090 @default.
• W2532584865 hasAuthorship W2532584865A5086306721 @default.
• W2532584865 hasAuthorship W2532584865A5088217204 @default.
• W2532584865 hasBestOaLocation W25325848651 @default.
• W2532584865 hasConcept C126322002 @default.
• W2532584865 hasConcept C164705383 @default.
• W2532584865 hasConcept C203092338 @default.
• W2532584865 hasConcept C2776708134 @default.
• W2532584865 hasConcept C2777028646 @default.
• W2532584865 hasConcept C2777698277 @default.
• W2532584865 hasConcept C2777849778 @default.
• W2532584865 hasConcept C2778583881 @default.
• W2532584865 hasConcept C2780400711 @default.
• W2532584865 hasConcept C45393284 @default.
• W2532584865 hasConcept C500558357 @default.
• W2532584865 hasConcept C535046627 @default.
• W2532584865 hasConcept C71924100 @default.
• W2532584865 hasConceptScore W2532584865C126322002 @default.
• W2532584865 hasConceptScore W2532584865C164705383 @default.

• next